Loftus, Joseph C <br/><br/>
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.  [electronic resource] 

 -  Molecular cancer research : MCR  Aug 2013 
 - 865-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1557-3125 
<br/><br/><label>Standard No.: </label>10.1158/1541-7786.MCR-13-0008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Astrocytes--physiology<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cell Survival<br/>Chickens<br/>Dacarbazine--analogs & derivatives<br/>Drug Resistance, Neoplasm--genetics<br/>Epilepsy<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Gene Knockdown Techniques<br/>Glioblastoma--drug therapy<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Mice, Transgenic<br/>NF-kappa B--antagonists & inhibitors<br/>Neoplasm Invasiveness--genetics<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Receptors, Tumor Necrosis Factor--genetics<br/>Signal Transduction--drug effects<br/>Temozolomide<br/>Xenograft Model Antitumor Assays